Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 6/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | THPO | P40225 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10000765 | 0.99 | SLC6A4 (0.97) | SLC6A4SLC6A3SIGMAR1SLC6A2SMN1; SMN2 | |
| Vanoxerine SCHEMBL725103 | 0.99 | SLC6A4 (1.00) | SLC6A4SLC6A3SIGMAR1SLC6A2SMN1; SMN2 | |
| Vanoxerine SCHEMBL15541249 | 0.99 | SLC6A4 (1.00) | SLC6A4SLC6A3SIGMAR1SLC6A2SMN1; SMN2 | |
| Vanoxerine SCHEMBL3014060 | 0.97 | SLC6A4 (0.95) | SLC6A4SLC6A3SIGMAR1SLC6A2SMN1; SMN2 | |
| SCHEMBL6254945 | 0.95 | SLC6A4 (0.90) | SLC6A4SLC6A3SIGMAR1SLC6A2SMN1; SMN2 | |
| SCHEMBL24221220 | 0.94 | SLC6A4 (0.88) | SLC6A4SLC6A3SIGMAR1SLC6A2SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11374533 | 0.94 | SLC6A4 (0.90) | SLC6A4SLC6A3SIGMAR1SLC6A2SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11380714 | 0.92 | SLC6A4 (0.88) | SLC6A4SLC6A3SIGMAR1SLC6A2SMN1; SMN2 | |
| Vanoxerine SCHEMBL11373792 | 0.91 | SLC6A4 (0.83) | SLC6A4SLC6A3SIGMAR1SLC6A2SMN1; SMN2 | |
| Vanoxerine SCHEMBL11373788 | 0.91 | SLC6A4 (0.83) | SLC6A4SLC6A3SIGMAR1SLC6A2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1434 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4618976-A1 | COMPOSITIONS AND METHODS OF TREATING NEUROLOGICAL CONDITIONS | Dri Biosciences Corporation (US) | 2025-09-24 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-12310934-B2 | Methods of treatment of spontaneous preterm birth | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-05-27 | — | — | US | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| US-20240398978-A1 | Compositions and Methods for Treating Dopamine Disorders | METAQOR LLC (US) | 2024-12-05 | — | — | US | claimed |
| EP-3386493-B1 | DBH INHIBITORS FOR TREATING OR PREVENTING MEMORY LOSS | UNIV BRANDEIS (US) | 2024-11-20 | — | — | EP | claimed |
| WO-2024107961-A1 | COMPOSITIONS AND METHODS OF TREATING NEUROLOGICAL CONDITIONS | DRI BIOSCIENCES CORPORATION (US) | 2024-05-23 | — | — | WO | claimed |
| US-20240148745-A1 | COMPOUNDS FOR USE IN PROGRESSIVE MULTIPLE SCLEROSIS | FONDAZIONE CENTRO SAN RAFFAELE (IT) | 2024-05-09 | — | — | US | claimed |
| WO-2002030422-A1 | USE OF DEFINED SUBSTANCES THAT BIND TO THE SIGMA RECEPTOR FOR COMBATING SARCOMA AND CARCINOMA | MERCK PATENT GMBH (DE) | 2002-04-18 | — | — | WO | claimed |
| US-20020019421-A1 | Compositions and therapy for substance addiction | BIBERMAN RONI (IL) | 2002-02-14 | — | — | US | claimed |
| JP-2001506978-A | — | — | 2001-05-29 | — | — | JP | claimed |
| EP-0937053-A1 | SUSTAINED-RELEASE DERIVATIVES OF HYDROXYLATED ANALOGS OF SUBSTITUTED 1- 2 BIS(ARYL)METHOXY]ETHYL]-PIPERAZINES AND -HOMOPIPERAZINES AND THEIR USE AS NONCOMPETITIVE ANTAGONISTS OF DOPAMINE REUPTAKE | THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services (US) | 1999-08-25 | — | — | EP | claimed |
| WO-1998018769-A1 | SUSTAINED-RELEASE DERIVATIVES OF HYDROXYLATED ANALOGS OF SUBSTITUTED 1-[2[BIS(ARYL)METHOXY]ETHYL]-PIPERAZINES AND -HOMOPIPERAZINES AND THEIR USE AS NONCOMPETITIVE ANTAGONISTS OF DOPAMINE REUPTAKE | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-05-07 | — | — | WO | claimed |
| US-5366975-A | Pesticides | THE GENERAL HOSPITAL CORPORATION (US) | 1994-11-22 | — | — | US | claimed |
| EP-0485512-A4 | SLOWLY DISSOCIATING (TIGHT BINDING) DOPAMINE, SEROTONIN OR NOREPINEPHRINE REUPTAKE INHIBITORS AS COCAINE, AMPHETAMINE AND PHENCYCLIDINE ANTAGONISTS | US HEALTH (US) | 1992-08-26 | — | — | EP | claimed |
| EP-0485512-A1 | SLOWLY DISSOCIATING (TIGHT BINDING) DOPAMINE, SEROTONIN OR NOREPINEPHRINE REUPTAKE INHIBITORS AS COCAINE ANTAGONISTS. | THE UNITED STATES OF AMERICA as represented by the Secretary UNITED STATES DEPARTMENT OF COMMERCE (US) | 1992-05-20 | — | — | EP | claimed |
| WO-1991001732-A1 | SLOWLY DISSOCIATING (TIGHT BINDING) DOPAMINE, SEROTONIN OR NOREPINEPHRINE REUPTAKE INHIBITORS AS COCAINE, AMPHETAMINE AND PHENCYCLIDINE ANTAGONISTS | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, UNITED STATES DEPARTMENT OF COMMERCE (US) | 1991-02-21 | — | — | WO | claimed |
| US-4202896-A | DOPAMINERGIC ACTIVITY | GIST-BROCADES N.V. (NL) | 1980-05-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | SLC6A4 1763/4885SLC6A3 1329/4885SIGMAR1 554/4885 |
| US-20240398978-A1 | Compositions and Methods for Treating Dopamine Disorders | SLC6A3, SNCA, CLTA | SLC6A4 42/4885SLC6A3 1/4885SIGMAR1 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.